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 Human corneal endothelial cells (HCEC) do not normally
proliferate in vivo [1,2]; however, they are able to divide in
response to wounding in ex vivo corneas [3] and will prolifer-
ate in culture [4,5] when stimulated by appropriate growth
promoting agents. Studies exploring the relative proliferative
capacity of HCEC have demonstrated that HCEC from older
donors (>50 years old) are less responsive to mitogens than
cells from younger donors (<30 years old) [3-6]. For example,
epidermal growth factor (EGF) is able to stimulate prolifera-
tion in HCEC [5-9], but the relative level of DNA synthesis
and the number of cells that divide in response to EGF stimu-
lation is relatively low, particularly in cells from older donors
[5]. Studies are being conducted in this laboratory to identify
the molecular basis for this weak response to determine
whether it is possible to increase the sensitivity of HCEC to
EGF. This could lead to development of methods to increase
proliferation of HCEC in vivo or in donor corneas to be used
for transplantation, resulting in increased endothelial cell den-
sity. It may also improve methods for use of HCEC in regen-
erative therapies.
Several growth factors, including EGF, signal via mem-
brane-bound receptors with intrinsic protein-tyrosine kinase
activity. Receptors of this type are termed receptor tyrosine
kinases (RTKs). In the case of the EGF receptor (EGFR), the
RTK activity is stimulated by ligand binding, resulting in
autophosphorylation of specific tyrosine residues (Tyr992 and
Tyr1148), which are located within the COOH-terminal intra-
cellular domain of the receptor [10]. This tyrosine phosphory-
lation is reversible and plays an important role in activating
and regulating downstream cellular pathways. Downstream
mediators of EGF-induced signaling include phospholipase
C-γ (PLC-γ) and its downstream calcium- and protein kinase
C (PKC) cascades, as well as MAP kinases, including ERK/
MAPK [10-12]. After ligand binding and tyrosine
autophosphorylation, EGFR is rapidly internalized into
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Purpose: Human corneal endothelial cells (HCEC), particularly from older donors, only proliferate weakly in response to
EGF. The protein tyrosine phosphatase, PTP1B, is known to negatively regulate EGF-induced signaling in several cell
types by dephosphorylating the epidermal growth factor receptor (EGFR). The current studies were conducted to deter-
mine whether PTP1B plays a role in regulating cell cycle entry in HCEC in response to EGF stimulation.
Methods: Donor corneas were obtained from the National Disease Research Interchange and accepted for study based on
established exclusion criteria. PTP1B was localized in the endothelium of ex vivo corneas and in cultured cells by immu-
nocytochemistry. Western blot analysis verified PTP1B protein expression in HCEC and then compared the relative ex-
pression of EGFR and PTP1B in HCEC from young (<3 years old) and older donors (>60 years old). The effect of
inhibiting the activity of PTP1B on S-phase entry was tested by comparing time-dependent BrdU incorporation in
subconfluent HCEC incubated in the presence or absence of the PTP1B inhibitor, CinnGEL 2Me, before EGF stimulation.
Results: PTP1B was localized in a punctate pattern mainly within the cytoplasm of HCEC in ex vivo corneas and cultured
cells. Western blots revealed the presence of three PTP1B-positive bands in HCEC and the control. Further western blot
analysis showed no significant age-related difference in expression of EGFR (p=0.444>0.05); however, PTP1B expres-
sion was significantly higher in HCEC from older donors (p=0.024<0.05). Pre-incubation of HCEC with the PTP1B
inhibitor significantly increased (p=0.019<0.05) the number of BrdU positive cells by 48 h after EGF stimulation.
Conclusions: Both immunolocalization and western blot studies confirmed that PTP1B is expressed in HCEC. Staining
patterns strongly suggest that at least a subset of PTP1B is localized to the cytoplasm and most likely to the endoplasmic
reticulum, the known site of EGFR/PTP1B interaction following EGF stimulation. PTP1B expression, but not EGFR
expression, was elevated in HCEC from older donors, suggesting that the reduced proliferative activity of these cells in
response to EGF is due, at least in part, to increased PTP1B activity. The fact that inhibition of PTP1B increased the
relative number of cells entering S-phase strongly suggests that PTP1B helps negatively regulate EGF-stimulated cell
cycle entry in HCEC. These results also suggest that it may be possible to increase the proliferative activity of HCEC,
particularly in cells from older donors, by inhibiting the activity of this important protein tyrosine phosphatase.
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endosomes and remains active for several minutes before ei-
ther being sorted to lysosomes for degradation or recycled back
to the plasma membrane. The fate of the receptor and the out-
put of the signaling process depend on continued ligand bind-
ing and kinase activity [13,14].
Protein tyrosine phosphatases (PTPs) comprise a large
family of receptor-like and non-receptor enzymes that share a
highly conserved catalytic domain specific for phosphotyrosine
hydrolysis. PTPs act as “on” and “off” switches for numerous
signaling events, thus acting as regulators of the signaling pro-
cess [15,16]. PTP1B is a widely expressed non-receptor PTP
that was originally identified in placenta [17]. Sequencing stud-
ies indicate that PTP1B consists of 435 amino acids with a
molecular weight of approximately 50 kDa [18-20]. PTP1B
contains a phosphatase catalytic domain at its NH2-terminus
(residues 40-276), a region containing proline-rich motifs that
promote interaction with proteins containing SH2-domains.
PTP1B also contains a COOH-terminal hydrophobic region
(residues 401-431) that is necessary and sufficient to localize
PTP1B to the cytoplasmic face of the endoplasmic reticulum
[18,20-22] and nuclear envelope [23]. PTP1B interacts with
and dephosphorylates several RTKs, including EGFR [24-26],
the PDGF-BB receptor [26,27], and the FGF receptor [27],
thereby attenuating ligand-induced downstream signaling.
Besides its role in regulating growth factor-based signaling,
PTP1B is also involved in regulating insulin- and leptin-in-
duced signaling. As a result, several laboratories are actively
developing PTP1B inhibitors that will interfere with its nega-
tive regulation of these important signaling processes [28-34].
Previous studies from this laboratory [35] demonstrated
the expression of several PTPs, including, PTP1B, SHP-1,
SHP-2, PTP-µ, and the dual-specificity phosphatase, PTEN,
in rat corneal endothelial cells both in ex vivo corneas and in
culture. Treatment of subconfluent rat corneal endothelial cells
with the general phosphatase inhibitor, sodium orthovanadate
(SOV), increased the relative number of cells entering the cell
cycle, as indicated by positive staining for Ki67, a marker of
actively cycling cells [36]. This result strongly suggested that
phosphatase activity helps suppress cell cycle entry in corneal
endothelium. Subsequent studies concentrated on the role of
PTP1B in the regulation of EGFR signaling in rat corneal en-
dothelium [37]. Western blot studies indicated that EGF in-
duces phosphorylation of EGFR-Tyr992. Incubation of these
cells with the PTP1B inhibitor, CinnGEL 2Me, both sustained
EGF-induced phosphorylation of EGFR-Tyr992 and increased
the number of cells entering the cell cycle, as indicated by
immunostaining for Ki67. Together, these findings provide
evidence that PTP1B plays a role in the negative regulation of
EGFR signaling in rat corneal endothelial cells, at least at the
level of Tyr992 phosphorylation.
The current studies move the inquiry from rat to human
corneal endothelial cells. The goal of these studies was to de-
termine whether PTP1B plays a role in negatively regulating
cell cycle entry in EGF-stimulated HCEC. Studies were con-
ducted to verify expression of PTP1B in human corneal en-
dothelium both in ex vivo corneas and in culture, to compare
the relative expression of PTP1B and EGFR in HCEC cul-
tured from young and older donors, and to determine whether
inhibition of the activity of PTP1B could increase cell cycle
entry in HCEC in response to EGF stimulation.
METHODS
Isolation and culture of human corneal endothelial cells:
Donor human corneas were obtained through National Dis-
ease Research Interchange (NDRI, Philadelphia, PA). In ac-
cepting corneas from NDRI, the overall health of the donor
before death was considered and tissue was rejected from do-
nors with previous history or treatment that might damage the
corneal endothelium, as indicated in the exclusion criteria that
have been reported previously [6]. Handling of donor infor-
mation by the source eye bank, NDRI, and this laboratory
adhered to the tenets of the Declaration of Helsinki 1983 revi-
sion in protecting donor confidentiality. All corneas were pre-
served in Optisol-GS (Baush & Lomb, Rochester, NY) at 4
°C. Table 1 presents donor information for all corneas used in
the current studies. For tissue culture studies, endothelial cells
were isolated from donor corneas and cultured according to
previously described protocols [4,5]. Briefly, Descemet’s mem-
brane with attached endothelium was dissected in small strips
and then incubated in culture medium overnight at 37 °C to
stabilize the cells. Culture medium consisted of OptiMEM-I
(Invitrogen-Gibco, Grand Island, NY) supplemented with 8%
fetal bovine serum (FBS; Hyclone, Logan, UT), 5 ng/ml epi-
dermal growth factor (EGF; Upstate Biotechnologies, Lake
Placid, NY), 20 ng/ml nerve growth factor (NGF; Biomedical
Technologies, Stoughton, MA), 100 µg/ml bovine pituitary
extract (Biomedical Technologies), 20 µg/ml ascorbic acid
(Sigma-Aldrich, St. Louis, MO), 200 mg/ml calcium chloride,
0.08% chondroitin sulfate (Sigma-Aldrich), 50 µg/ml gentami-
cin (Invitrogen-Gibco), and antibiotic-antimycotic solution
(Sigma-Aldrich) diluted 1:100. After gentle centrifugation, the
medium was removed and 0.02% EDTA was added for 1 h at
37 °C to separate the cells. Following centrifugation, the iso-
lated cells and pieces of Descemet’s membrane still contain-
ing attached cells were resuspended in culture medium, plated
in six-well tissue culture plates that had been pre-coated with
FNC Coating Mix (Biological Research Faculty & Facility,
Inc., Ijamsville, MD), and incubated at 37 °C in a 5% CO2
humidified atmosphere. Medium was changed every-other day.
After cells reached confluence, they were subcultured at a 1:2
ratio. HCEC at passage 2 were used for all experiments.
Immunocytochemical localization of PTP1B in ex vivo
corneas and cultured HCEC:  Table 1 provides information
regarding the donor corneas used for these studies. Corneas
from four different donors were used to localize PTP1B in ex
vivo corneal endothelium, while corneas from two different
donors were used as a source of cells for culture. Corneas were
washed three times with culture medium and incubated over-
night (37 °C, 5% CO2) to stabilize the cells. After incubation,
the tissues were washed with phosphate-buffered saline (PBS;
Invitrogen) and fixed for 10 min in 100% methanol at -20 °C.
All further incubations were at room temperature. Corneas
were cut in quarters, washed in PBS three times for 10 min
each, then permeabilized for 10 min in PBS containing 1%
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Triton X-100 (Sigma-Aldrich). Before they were stained with
antibodies, tissues were washed with 0.1% Triton X-100 in
PBS and incubated for 10 min in blocking buffer containing
0.1% Triton X-100 and 4% BSA in PBS. After a 2 h incuba-
tion in mouse-anti-PTP1B (PH01; Calbiochem) diluted 1:50
in 0.1% Triton X-100 in PBS, the tissues were rinsed with
0.1% Triton X-100 in PBS and reincubated for 10 min in block-
ing buffer. Corneas were then incubated for 1 h in FITC-con-
jugated donkey anti-mouse IgG (Jackson ImmunoResearch),
diluted 1:50 with 0.1% Triton X-100 in PBS. Tissue incubated
in secondary antibody alone acted as a negative control. Each
corneal quarter was mounted endothelial-side up on a glass
slide. Coverslips were mounted in medium containing
propidium iodide (PI; Vector Laboratories, Burlingame, CA)
to stain all nuclei. Digital images were obtained using a Leica
TSC-SP2 confocal microscope (Bannockburn, IL). A Z-series
through the tissue was captured with a step size of 0.5 µm per
image. Z-series images were collapsed onto a single image
plane by projecting the maximal pixel intensity of the images.
For immunolocalization of PTP1B in cultured cells, Passage-
2 HCEC were grown to approximately 50% confluence. HCEC
were then washed, fixed, and processed for immunostaining
of PTP1B as described for the ex vivo corneas. Cells incu-
bated in secondary antibody alone acted as negative controls.
Staining of cultured cells was visualized using an Eclipse E800
Nikon Microscope with VFM Epi-Fluorescence Attachment
(Nikon, Inc., Melville, NY) equipped with a Spot digital cam-
era and Spot Advanced version 4.5 CE software (Diagnostic
Instruments, Sterling Heights, MI).
Western blot verification of PTP1B expression in HCEC:
HCEC were cultured from a newborn and a 74-year-old do-
nor as indicated in Table 1. Protein was extracted from
confluent Passage-2 cells by incubating cells for 30 min at 4
°C in lysis buffer containing 1% Triton X-100, 250 mM NaCl,
2 mM EDTA, 50 mM Tris-HCl (pH 7.4), 10 µg/ml aprotinin,
10 µg/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride, 50
mM sodium fluoride, and 0.1 mM sodium orthovanadate (all
from Sigma-Aldrich), followed by homogenization and cen-
trifugation. The protein concentration of the supernatants was
determined spectrophotometrically. Equal concentrations of
soluble protein were loaded on 10% Bis-Tris gels (Invitrogen)
for SDS-PAGE and then electrophoretically transferred to a
polyvinylidene difluoride (PVDF) membrane (Millipore,
Bedford, MA). A commercially prepared whole cell lysate from
SW480 cells, a human colonic adenocarcinoma cell line (Santa
Cruz Biotechnology Inc., Santa Cruz, CA), acted as a positive
control for PTP1B. Non-specific binding was blocked by in-
cubation of the membranes for 1 h at room temperature in 5%
non-fat dry milk and 0.1% Triton X-100 in PBS. Membranes
were then incubated overnight at 4 °C with 1.25 µg/ml mouse
anti-PTP1B (PH01, as above). Blots were rinsed three times
for 10 min each with 0.1% Triton X-100 in PBS and then in-
cubated 1 h at room temperature with HRP-conjugated don-
key anti-mouse IgG, diluted 1:5000. Primary and secondary
antibodies were diluted with 5% non-fat dry milk, 0.1% Tri-
ton X-100 in PBS. Membranes were washed three times 10
min with 0.1% Triton X-100 in PBS, and antibody binding
was visualized using a chemiluminescent substrate
(SuperSignal West Pico; Pierce, Rockford, IL).
Western blot analysis of EGFR and PTP1B expression in
HCEC from young and older donors:  HCEC were cultured
from four young and four older donors as indicated in Table 1.
Note that one sample from a newborn donor and the sample
from the 74-year old donor were also used for western blot
verification of PTP1B as described above. Protein was ex-
tracted from passage 2 cells as above and supernatants were
stored at -80 °C until used for analysis. Polyacrylamide gel
electrophoresis and electrophoretic transfer of peptides to
PVDF membranes were performed as previously described.
Whole cell lysate from SW480 cells acted as a positive con-
trol for PTP1B, while protein from EGF-stimulated A431 cells
(Santa Cruz) acted as a positive control for EGFR. Non-spe-
cific binding was blocked by incubation for 1 h at room tem-
perature in 5% non-fat dry milk and 0.1% Triton X-100 in
PBS. Membranes were incubated overnight at 4 °C with ei-
ther 1.25 µg/ml mouse anti-PTP1B (PH01, as above) or rab-
bit anti-EGF receptor (1:1,000; Cell Signaling Technology Inc.,
Danvers, MA). Blots were rinsed and then incubated 1 h at
room temperature with either HRP-conjugated donkey anti-
mouse IgG, diluted 1:5000 to detect PTP1B, or HRP-conju-
gated donkey anti-rabbit IgG, diluted 1:2,000 to detect EGFR.
Membranes were washed three times 10 min with 0.1% Tri-
ton X-100 in PBS, and antibody binding was visualized using
a chemiluminescent substrate (SuperSignal West Pico; Pierce,
Rockford, IL). To prepare controls for protein loading, bound
antibodies were stripped from membranes by incubation for
15 min at room temperature in buffer containing 2% SDS,
62.5 mM Tris-HCl (pH 6.8) and 100 mM 2-mercaptoethanol
(all from Sigma) and reprobed with 1 µg/ml mouse anti-β-
actin (Sigma) diluted in 5% non-fat dry milk, 0.1% TritonX-
100 in PBS followed by incubation in HRP-conjugated don-
key anti-mouse IgG diluted 1:10,000. Studies were conducted
in duplicate. Semi-quantitative analysis was performed by
densitometry using an image-analysis software program (NIH
Image-J 1.38; National Institutes of Health, Bethesda, MD).
Protein expression was represented as a value relative to that
of β-actin. Statistical analysis was performed using unpaired
Student’s t-test. A p<0.05 was considered statistically signifi-
cant.
BrdU incorporation following EGF stimulation (+/-)
PTP1B inhibitor:  HCEC cultured from four donors were used
for these studies (see Table 1). To wean confluent passage 1
cells from the 8% FBS and growth factors present in the nor-
mal culture medium, cells were incubated for four days be-
fore subculture in medium containing 4% FBS without addi-
tional growth factors or pituitary extract. HCEC were then
trypsinized, seeded into four-well chamber slides (Nalge Nunc
International, Naperville, IL) pre-coated with FNC Coating
Mix, and incubated for 48 h in medium containing 0.1% FBS
without added growth factors or bovine pituitary extract. This
concentration of FBS was tested previously and found to main-
tain the health of cultured HCEC without inducing prolifera-
tion (data not shown). Cells in one-half of the wells were pre-
incubated for 1 h in the same medium plus 25 µM CinnGEL
632Me (BIOMOL Research Laboratories Inc., Plymouth Meet-
ing, PA), a novel peptide inhibitor of PTP1B [38]. CinnGEL
2Me was prepared by reconstitution in dimethyl sulfoxide
(DMSO, Sigma-Aldrich) according to the supplier’s instruc-
tions. Control cells were pre-incubated for 1 h in culture me-
dium plus the same volume of DMSO. EGF (25 ng/ml), plus
0.5 µl of Cell Proliferation Labeling Reagent containing BrdU
(Amersham Biosciences, Buckinghamshire England), was then
added to all culture wells. At 0, 12, 24, and 48 h after EGF
stimulation, cells were fixed with 100% methanol at -20 °C.
Fixation, blocking and antibody incubation steps were the same
as those described above for immunocytochemical localiza-
tion of PTP1B. Mouse anti-BrdU was used as primary anti-
body and FITC-conjugated donkey anti-mouse IgG (diluted
1:200) was used as secondary antibody. Secondary antibody
alone acted as a negative control. Coverslips were mounted in
medium containing PI to stain all nuclei. Positive staining of
cultured cells was visualized using the Nikon Eclipse E800
microscope described above. Duplicates were prepared for
each time point and condition. Seven images were taken per
culture well with a 40X objective lens. NIH Image-J 1.38 was
used to count total PI-stained nuclei and total BrdU-positive
nuclei. The relative percent of BrdU incorporation was calcu-
lated for each donor and time point. The number of BrdU-
positive nuclei was then averaged for each time point. Differ-
ences in the counts were analyzed with Student’s unpaired t-
test. A p<0.05 was considered significant.
RESULTS
PTP1B localization in ex vivo human corneal endothelium and
in cultured HCEC:  Corneas from donors aged 18, 59, 61, and
66 years old were used for localization of PTP1B in the en-
dothelium in situ. Corneas from donors aged 16 and 55 years
old were sources of cultured HCEC. Positive staining for
PTP1B demonstrated the expression of this important phos-
phatase in HCEC. Representative images of PTP1B
immunostaining are presented in Figure 1. A similar pattern
of PTP1B staining was found in HCEC both in situ (Figure
1A,B) and in culture (Figure 1D). Intense punctate staining
for PTP1B was located within the cytoplasm, while some punc-
tate staining was also observed in nuclei. No staining was ob-
served in controls incubated in secondary antibody alone (Fig-
ure 1C,E). Comparison of the images shows no obvious age-
related difference in the relative localization pattern of HCEC
either in situ or in culture.
Verification of PTP1B protein expression in HCEC:  West-
ern blot studies were conducted to verify PTP1B protein ex-
pression in HCEC. Table 1 presents information regarding the
two donors used for this study. As seen in Figure 2, samples
extracted from passage 2 HCEC (lanes 1 and 2) yielded three
PTP1B-positive bands-a band at 50 kDa, as well as two addi-
tional bands migrating at approximately 48 kDa and 46 kDa.
The SW480 cell positive control (lane 3) yielded a total of
five bands-three corresponding to the same bands observed in
the HCEC samples and two additional lower molecular weight
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TABLE 1. DONOR INFORMATION
Time; Time from death to preservation (h). Days; Days from death to culture or fixation. The single asterisk indicates newborn and the double
asterisk indicates the same donor source as used for the western blot verification of PTP1B expression.
64bands at approximately 39 kDa and 37 kDa. Published studies
of PTP1B protein expression in several different cell types,
including HeLa cells, human diploid fibroblasts, CV-1 cells,
and COS-1 cells, indicate that gel electrophoresis of full-length
PTP1B yields a band with a relative molecular weight of ap-
proximately 50 kDa [18,20,21]. This strongly suggests that
the 50 kDa band found on the blots of HCEC corresponds to
full-length PTP1B. PTP1B has also been detected at some-
what lower molecular weights. For example, bands of approxi-
mately 48 kDa [39] and 46 kDa [21] have been observed and
appear to represent truncated forms of PTP1B that are miss-
ing the COOH-terminal hydrophobic domain [21]. Thus, the
48 kDa and 46 kDa bands found in all three samples in the
current study appear to represent truncated forms of PTP1B.
Non-specific proteolytic cleavage of PTP1B can yield a band
migrating at approximately 37 kDa [17,20,21]. Two bands
migrating around 39 kDa and 37 kDa were visible in the com-
mercially prepared lysate of SW480 cells, suggesting that a
portion of PTP1B was nonspecifically cleaved in this sample.
These lower molecular weight bands were not detected in the
samples prepared from HCEC. Together, these results veri-
fied the expression of PTP1B in HCEC and provided sugges-
tive evidence that this protein tyrosine phosphatase exists in
multiple forms within the cell. Differences in the relative den-
sities of the three PTP1B bands were also noted. For example,
in the HCEC sample in lane 1, the 50 kDa band density ap-
peared to be higher than that of either the 48 kDa or 46 kDa
bands, whereas, in the sample in lane 2, the 46 kDa band ap-
peared denser than the 50 kDa band. The fact that intra-sample
differences were observed in this study was important, be-
cause it affected how total PTP1B expression was calculated
in the comparative western blot studies described below. In
addition, the protein samples used for this study were obtained
from a newborn and a 74-year-old donor. It is possible that the
observed intra- and/or inter-sample differences in relative den-
sity of the three PTP1B-positive bands were due to age-re-
lated alterations in PTP1B expression. This possibility was
further explored in the comparative studies described below.
Relative PTP1B and EGF receptor protein expression in
HCEC from young and older donors:  Previous studies from
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Figure 1. Representative images of PTP1B localization in ex vivo human corneal endothelium and in cultured HCEC.  A: Representative
image of PTP1B (green) staining in the endothelium of a cornea obtained from a 59-year-old donor. PTP1B is localized in a punctate pattern
mainly within the cytoplasm. Some punctate staining is also visible in nuclei (red). Note that larger dots of intense stain can be observed
scattered within the tissue or on individual cells. This appears to be due to non-specific antibody deposition, although all antibodies were
centrifuged at high-speed before use. B: Higher magnification image of HCEC in ex vivo corneal tissue showing more detail of the PTP1B
localization pattern. C: Negative control of ex vivo tissue in which corneas were incubated with secondary antibody alone. Image is an overlay
from both the FITC and rhodamine channels. D: PTP1B staining in subconfluent HCEC cultured from a 55-year-old donor results in a similar
punctate pattern in the cytoplasm and nucleus. E: Negative control in which cells were incubated with secondary antibody only. Image is an
overlay from both the FITC and rhodamine channels. green: PTP1B. red: Propidium iodide. Original magnification for A, C, D, and E: 40X.
Original magnification for B: 100X.
65this laboratory demonstrated that HCEC are able to prolifer-
ate in response to EGF, but that HCEC cultured from older
donors (>50 years old) are less responsive than cells from
young donors (<30 years old) [5,6]. It is possible that, in HCEC
from older donors, the relative expression of EGF receptors
might be reduced, leading to a weaker response to EGF. Since
PTP1B is known to dephosphorylate activated EGFRs, it is
also possible that there may be an age-related difference in
the relative expression of PTP1B in HCEC from older donors
that would underlie the observed difference in response to EGF.
Western blot studies were therefore conducted to compare the
relative protein expression of EGFR and PTP1B in HCEC.
Protein samples were prepared from confluent passage 2 cells
cultured from four young (two newborns, 2-year old and 3-
year old) and four older donors (aged 60, 66, 74, and 78 years
old). Table 1 provides more information and indicates that one
newborn donor sample and the sample from the 74-year-old
donor used in these studies were also used for the western blot
study described above. Results are presented in Figure 3. Fig-
ure 3A shows that EGFR protein was detected in all HCEC
samples. A band of the same relative molecular weight was
detected in EGF-stimulated A431 cells, which acted as a posi-
tive control for the western blot (data not shown). The relative
band density of EGFR tended to vary from donor-to-donor;
however, when band densities were normalized to β-actin and
average band densities compared, there was no statistically
significant difference (p=0.444>0.05) in average EGFR ex-
pression between the two age-groups (Figure 3B). As initially
observed in the western blot study discussed above and shown
in the expanded comparative study in Figure 3A, the relative
density of each of the three PTP1B-positive bands tended to
vary from sample to sample; however, there was no consis-
tent, age-related intra-sample density pattern observed. To
calculate total PTP1B expression in each donor sample, the
density of all three bands was added together and the total
density was then normalized to β-actin. The total density for
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Figure 2. Western blot detection of PTP1B protein bands in HCEC.
Confluent Passage-2 HCEC were cultured from a newborn (lane 1)
and a 74-year-old donor (lane 2) and processed for western blot de-
tection of PTP1B. A commercially prepared whole cell lysate of
SW480 cells was used as a positive control (lane 3). Blots showed
that the two HCEC samples yielded a band at approximately 50 kDa,
indicating the presence of full-length PTP1B, as well as two addi-
tional bands of approximately 48 kDa and 46 kDa, possibly repre-
senting truncated forms. The same three bands were observed in the
SW480 positive control sample, as well as lower molecular weight
bands around 39-37 kDa that may result from non-specific proteolytic
cleavage. Note the variability in density of the three PTP1B-positive
bands within the two HCEC samples.
Figure 3. Comparison of EGFR and PTP1B protein expression in
HCEC cultured from 4 young and 4 older donors.  A: Western blots
demonstrate the relative expression of EGFR and PTP1B in each of
the 8 donor samples. EGFR was expressed in all 8 samples, although
the band density varied somewhat among the samples. Three PTP1B
bands were observed in most samples. These bands are indicated
within brackets. Blots for the positive controls for EGFR (EGF-treated
A431cells) and PTP1B (SW480 cells) are not shown, but bands were
obtained at the same relative molecular weights as in the HCEC
samples. β-Actin was used as a loading control for both EGFR and
PTP1B. B: Comparison of the average band density for EGFR and
PTP1B in samples from young and older donors. Bars represent SEM.
Asterisk indicates statistical significance (p=0.024).
66PTP1B in each sample was then used to calculate the average
total density of PTP1B within the two age-groups. As shown
in Figure 3B, the average total density of PTP1B was signifi-
cantly higher (p=0.024<0.05) in HCEC samples from older
donors compared with young donors, indicating that PTP1B
is expressed at higher levels in HCEC from older donors.
PTP1B inhibitor increases BrdU incorporation follow-
ing EGF stimulation:  Experiments were then conducted to
determine whether inhibition of PTP1B activity could increase
S-phase entry in HCEC. The inhibitor chosen for this study
was CinnGEL 2Me. The free cinnamic acid component of
CinnGEL 2Me inhibits PTP1B (IC50=1.3 µM), while the me-
thyl ester is added for cell permeability. According to the sup-
plier, CinnGEL 2Me is hydrolyzed to active inhibitor by in-
tracellular esterases. In studies of rat corneal endothelial cells
[37], the effect of CinnGEL 2Me was tested at a final concen-
tration of 1 mM and found to increase cell cycle entry as indi-
cated by quantification of Ki67 staining. Prior to this study in
HCEC, a range of CinnGEL 2Me concentrations was tested
both for its effect on S-phase entry and on cell viability. A
final concentration of 25 µM was found to be optimal and was
used for the subsequent studies. HCEC were cultured from
donors aged 16 and 18 and two different 72-year-old donors
(see Table 1). Subconfluent Passage-2 cells were pretreated
for 1 h with 25 µM CinnGEL 2Me. Since CinnGEL 2Me re-
quires reconstitution in DMSO, control cells were pre-treated
for 1 h with the same concentration of DMSO minus the in-
hibitor. Cells were then stimulated with 25 ng/ml EGF and
stained at 0, 12, 24, and 48 h for BrdU incorporation to test
the effect of PTP1B inhibition on S-phase entryE cultured.
For these studies, BrdU was used to specifically indicate S-
phase entry. Figure 4A presents a representative example of
BrdU staining in HCEC from one of the 72 year-old donors.
No BrdU staining was observed at the 0 time point or in con-
trol tissue incubated in secondary antibody only (data not
shown). Images show a gradual increase in the relative num-
ber of BrdU-stained cells. Figure 4B shows that, under both
conditions, the average number of BrdU-positive cells in-
creased in a time-dependent manner. At the 12, 24, and 48 h
time points, the average BrdU incorporation tended to be higher
in cells treated with the PTP1B inhibitor. By 48 h after EGF
stimulation, BrdU incorporation was significantly higher
(p=0.019<0.05) in CinnGEL 2Me-treated cells.
DISCUSSION
 Previous studies documented the expression of PTP1B in rat
corneal endothelial cells [35,37]; however, the current studies
are the first to demonstrate expression of this important PTP
in HCEC. Results indicate that PTP1B is expressed in HCEC
and that the pattern of PTP1B localization is similar in ex vivo
endothelium and in cultured cells, indicating that no gross
change in PTP1B location occurs upon culturing. The punc-
tate cytoplasmic pattern observed in HCEC is consistent with
that observed in ex vivo rat corneal endothelium [35]. A simi-
lar pattern has been demonstrated in several cell types
[21,22,39-41] and suggests that, in HCEC, PTP1B is mainly
localized to the cytoplasmic surface of the endoplasmic reticu-
lum. Some punctate staining was also observed in the nuclei
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Figure 4. Effect of PTP1B inhibitor on cell cycle entry in response to
EGF stimulation.  Subconfluent HCEC were pre-incubated for 1 h in
medium containing either DMSO alone or 25 µM of the PTP1B in-
hibitor, CinnGEL 2Me, diluted in DMSO. Following this pre-incu-
bation step, 25 ng/ml EGF was added to all cultures. Samples were
taken for BrdU staining at 0, 12, 24, or 48 h after EGF addition. A:
Representative images showing BrdU staining (green) in subconfluent
HCEC from a 72 year-old donor incubated in either DMSO alone or
in CinnGEL 2Me PTP1B inhibitor. Cultures were counterstained with
propidium iodide (PI) to reveal all nuclei (red). Final magnification:
400X. B: Bar graph shows the average percent of BrdU-positive
HCEC at each time point. Bars represent SEM. The asterisk indi-
cates statistical significance at p=0.019.
67of HCEC both in situ and in culture. This finding is consistent
with studies in other cell types [21,23], which have shown
that at least a subset of PTP1B may be associated with the
nuclear membrane. Co-localization of PTP1B with specific
membrane markers will be needed to verify its specific sub-
cellular localization. PTP1B is implicated in dephosphoryla-
tion and inactivation of several plasma membrane-associated
RTKS, including EGFR [24-26]. Immunolocalization studies
in ex vivo rat corneal endothelium [37] demonstrated a time-
dependent internalization of EGFR at cell borders following
EGF stimulation, suggesting that EGFR could interact with
and be regulated by PTP1B within the cell. Similar studies are
needed to verify that this interaction also occurs in HCEC. It
will also be important to clearly demonstrate that PTP1B is
directly involved in time-dependent dephosphorylation of
EGFR following EGF stimulation of HCEC.
Protein extracts of HCEC, as well as the commercial
SW480 cell lysate that was used as a positive control, consis-
tently showed the presence of three bands for PTP1B on west-
ern blots-one band at 50kDa (the relative molecular weight
expected for full-length PTP1B) and two bands of approxi-
mately 48 kDa and 46 kDa. As discussed above, these two
lower molecular weight bands most likely correspond to trun-
cated forms of PTP1B. The exact nature and function of these
truncated forms is unclear and needs to be further investigated.
The bands identified on the blots of HCEC and SW480 cells
do not appear to correspond to PTP1B forms described in HeLa
cell extracts by Schievella, et al. [42]. Those studies identified
a single PTP1B band migrating more slowly than the 50 kDa
band in samples from cells synchronized in G2/M-phase with
nocodazole. This slower migrating form was identified as a
serine-phosphorylated (“mitotic”) form of PTP1B. In the cur-
rent studies, the position of the three PTP1B bands in HCEC
relative to that of the commercial molecular weight markers
and to the bands of the positive control indicates that the slow-
est migrating band in the HCEC samples corresponds to the
full-length 50kDa form of PTP1B and not to a slower migrat-
ing “mitotic” form. In addition, fully confluent cells were used
for these studies and the presence of mitotic cells in the cul-
tures is highly unlikely. Interestingly, the relative density of
the three bands differed among the HCEC samples. The spe-
cific nature of the two lower molecular weight forms and the
reason why their relative concentrations differ in HCEC re-
mains to be elucidated.
Previous studies from this laboratory demonstrated an age-
related decrease in the responsiveness of HCEC to EGF stimu-
lation [5,6]; however, the molecular basis for this decrease is
not known. One possibility is that the expression of EGFR
decreases in an age-related manner; however, results of the
current western blot studies demonstrate that the relative ex-
pression of EGFR protein did not differ significantly with
donor age. This finding differs from that of Lopez, et al. [43],
who used flow cytometry to quantify EGF receptors in cor-
neal cells. In that study, Passage-7 HCEC cultured from an
infant donor, which exhibited senescence characteristics, ex-
pressed a considerably higher number of EGF receptors
(>30,000/cell) than early passage cells from an infant donor
(5,142 ±2,412/cell). This discrepancy in results could be due
to differences exhibited by cells aged in culture through mul-
tiple passages versus early-passage cells cultured from young
and older donors or to the detection methods used for assay.
Results similar to those in the current study have been reported
in other cell types. For example, EGF-stimulated DNA syn-
thesis was found to be decreased in primary hepatocytes cul-
tured from 24 month-old rats compared to cells cultured from
6 month-old rats, although no age-related difference in EGFR
density or binding affinity was detected [44]. Similarly, de-
creased DNA synthesis was observed in human diploid fibro-
blasts aged by passage in culture without a concomitant change
in EGFR expression [45,46]. Together, these results suggest
that the difference in responsiveness to EGF exhibited by aged
cells may not be specifically due to differences in EGFR ex-
pression, but to decreased downstream signaling [45]. This
idea is supported by studies in mouse [47] and rat hepatocytes
[48], which found that decreased levels of DNA synthesis in
old mice were associated with decreased activation of ERK
and decreased tyrosine phosphorylation of EGFR. Studies of
in vitro aged human dermal fibroblasts by Tran, et al. [49]
demonstrated that EGF receptor autophosphorylation was sig-
nificantly decreased upon EGF stimulation, as was phospho-
rylation of the downstream mediator, Shc. These age-related
changes were paralleled by increased dephosphorylation of
EGFR, increased PTPase activity, and increased expression
of the protein tyrosine phosphatases, PTP1B and SHP-1. These
findings provide evidence that, with age, cells become less
sensitive to EGF stimulation due, at least in part, to increased
dephosphorylation of EGFR by PTPs, including PTP1B, re-
sulting in decreased downstream signaling. Interestingly, west-
ern blots of HCEC showed no significant age-related change
in EGFR expression, but did detect a statistically significant
increase in PTP1B expression in HCEC cultured from older
donors. Therefore, it is possible that the difference in respon-
siveness to EGF exhibited by HCEC from older donors is not
due to differences in EGFR expression but to decreased down-
stream signaling resulting from increased PTP1B-induced
EGFR dephosphorylation. This intriguing hypothesis requires
further testing.
To test whether PTP1B plays a role in the negative regu-
lation of EGF signaling in HCEC, we employed the commer-
cially available PTP1B inhibitor, CinnGEL 2Me. In previous
studies, treatment of rat corneal endothelial cells with this in-
hibitor before EGF stimulation resulted in an increase in Ki67-
positive cells [37]. Ki67 is a recognized marker of actively
cycling cells, because its expression is detectable in late G1-
phase through mitosis, but not in quiescent cells [37,50]. In
the current studies, we chose to use BrdU to more specifically
mark entry into S-phase of the cell cycle. Although EGF stimu-
lated S-phase entry both in the presence and absence of the
PTP1B inhibitor, inhibition of PTP1B resulted in a significant
increase in S-phase cells by 48 h after EGF addition, strongly
suggesting that PTP1B negatively regulates EGF-stimulated
proliferation. It should be noted that the population doubling
time (PD) of HCEC is quite slow. The average PD for HCEC
cultured from young donors is 46.25 h, while the PD for cells
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68from older donors is 90.25 [6]. Thus, it was not unexpected
that these results only showed a statistical significance 48 h
after EGF stimulation. Additional studies are needed to deter-
mine whether PTP1B inhibition will increase division of
HCEC, particularly from older donors.
In summary, PTP1B is expressed in HCEC, as well as in
rat corneal endothelial cells. Staining patterns strongly sug-
gest that at least a subset of PTP1B is localized to the cyto-
plasm and most likely to the endoplasmic reticulum-a site at
which PTP1B is known to dephosphorylate EGFR in other
cells. Interestingly, PTP1B expression, but not EGFR expres-
sion was elevated in HCEC from older donors. It is possible
that the reduced sensitivity of these cells to EGF stimulation
is due, at least in part, to increased PTP1B activity, resulting
in decreased downstream signaling and a reduced number of
cells entering the cell cycle. These findings are relevant to
understanding the molecular basis for the decreased prolif-
erative response of HCEC to EGF (and possibly to other RTKs)
and may lead to treatments to overcome decreased downstream
signaling by inhibiting PTP1B, thereby increasing prolifera-
tion and endothelial cell density.
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